CD274 and cancer: Those findings supported that the notion that the DMS signature of DNA methylation regulator patterns, combined with gene mutation signals, as promising to predict the efficacy of anti-CTLA-4/PD-1/PD-L1 immune checkpoint blockade therapy, and could contribute to guide more effective strategies for precision immunotherapy in cancer individuals.